Osteogenesis Imperfecta
Conditions
Brief summary
An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe Osteogenesis Imperfecta compared with a combination of historical and untreated prospective controls.
Interventions
BIOLOGICALBOOST cells
Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.
Sponsors
Karolinska University Hospital
Great Ormond Street Hospital for Children NHS Foundation Trust
University College, London
Universitätsklinikum Köln
UMC Utrecht
Leiden University Medical Center
Lund University
Karolinska Institutet
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Months
Healthy volunteers
No
Inclusion criteria
Postnatal Group: 1. Parent's/legal guardian's signed informed-consent form 2. Clinical diagnosis of OI type III or severe type IV AND 3. Molecular diagnosis of OI (Glycine substitution in the collagen triple-helix encoding region of either the COL1A1 or COL1A2 gene) 4. Age less than 18 months (calculated from gestational week 40+0, i.e. the corrected age) 5. Parent/legal guardian over 18 years of age Inclusion Criteria Prenatal Group: 1. Woman has signed the informed-consent form 2. Only women where termination of the pregnancy is no longer possible or where the women are committed to continue the pregnancy may be included in the trial 3. Suspicion of OI type III or severe type IV in the fetus on ultrasound findings AND 4. Molecular diagnosis of OI in the fetus (Glycine substitution in the collagen triple-helix encoding region of either the COL1A1 or COL1A2 gene) 5. Gestation age between 16+0 and 35+6 weeks+days 6. Pregnant woman over 18 years of age Inclusion Criteria Historical Control Group: 1. Parent's/legal guardian's signed informed-consent form 2. Clinical and molecular diagnosis of OI (Glycine substitution in the collagen triple-helix encoding region of either the COL1A1 or COL1A2 gene) 3. Data on fractures and growth is available 4. Parent/legal guardian over 18 years of age Inclusion Criteria Prospective Untreated Control Group: * Postnatal inclusion: The inclusion criteria for the postnatal group apply. * Prenatal inclusion: The inclusion criteria for the prenatal group apply, except inclusion criteria 2.
Exclusion criteria
Postnatal Group: 1. Existence of other known disorder that might interfere with the treatment, such as, but not limited to organ dysfunction (for example liver or renal failure or bronchopulmonary dysplasia), congenital heart defect, hypoxic encephalopathy l-lll, severe neurological problems, immune deficiencies, muscle diseases, severe malformations or syndromes diagnosed by clinical examination. 2. Any contraindication for invasive procedures such as a moderate/severe bleeding tendency 3. Known risk factors for clotting, such as, but not limited to previous blood clot, family history of clots, clotting disorder (inherited or acquired), heart failure, inflammatory disorders (for example lupus, rheumatoid arthritis, inflammatory bowel disease) 4. Positive Donor Specific Antibody-test 5. Known allergy/hypersensitivity to Fungizone and/or Gensumycin 6. Abnormal karyotype or other confirmed genetic syndromes 7. Oncologic disease (previous or current malignancy) 8. Inability to comply with the trial protocol and follow-up schedule 9. Inability to understand the information and to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events. | From baseline to the long-time follow-up (10 years after the first dose). | The primary endpoint is safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events (AEs), with specific focus on the following: 1. Vital signs in conjunction with the MSC administration 2. Transfusion reactions (administration toxicity, allergy, embolism) 3. Immune reaction with or without symptoms of inflammation, potentially resulting in rejection of the cells or development of donor-specific antibodies: * Allergy or Hypersensitivity responses to antibiotics or antimycotics * Development of Fetal Bovine Serum-specific antibodies * Hypersensitivity responses to Human Serum Albumin * Hypersensitivity to impurities in the IMP 4. Prenatal complications (miscarriage/intrauterine fetal death, premature birth, infection in utero or persistent \[\>1 min\] fetal bradycardia) in the prenatal group 5. Adverse effects of feto-maternal transmission of donor cells in the prenatal group 6. Tumourigenicity 7. Mortality/morbidity |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Numbers of fractures at birth. | Evaluated at birth. | Numbers of fractures at birth. |
| Growth (cm). | From baseline to the primary follow-up (6 and 12 months after the last dose) and thereafter assessed annually to the end of the long-time follow-up (10 years after the first dose). | Growth (cm) as assessed by clinician. |
| Growth (kg). | From baseline to the primary follow-up (6 and 12 months after the last dose) and thereafter assessed annually to the end of the long-time follow-up (10 years after the first dose). | Growth (kg) as assessed by clinician. |
| Change in clinical status of OI. | From baseline to the primary follow-up (6 and 12 months after the last dose) and thereafter assessed annually to the end of the long-time follow-up (10 years after the first dose). | Change in clinical status of OI based on parameters defined under efficacy assessments described in protocol, as assessed by OI clinician. |
| Assessment of biochemical bone turnover by analysis of the markers P-Calcium, P-Phosphate, P-Albumin, S-ALP, fP-PTH, S-25-OH Vitamin D, Bone specific S-ALP, S-CTx, S-Osteocalcin and U-DPD/Krea and U-NTx/Krea in blood and urine samples. | From baseline to the primary follow-up (6 and 12 months after the last dose) and thereafter assessed annually to the end of the long-time follow-up (10 years after the first dose). | Assessment of biochemical bone turnover. |
| Number of fractures. | From baseline to the primary follow-up (6 and 12 months after the last dose) and therafter assessed annually to the end of the long-time follow-up (10 years after the first dose). | Number of fractures. |
| Time (days) to first fracture after each stem cell administration. | From each dose of stem cells to the time point of the first fracture. Assessed up to 10 years after the first stem cell dose. | Time (days) to first fracture after each stem cell administration. |
| Change in bone-marrow density (g/cm2). | From baseline to the primary follow-up (6 and 12 months after the last dose) and thereafter assessed annually to the end of the long-time follow-up (10 years after the first dose). | Change in bone-marrow density (g/cm2). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Analysis of an array of cytokines and micro vesicles to evaluate paracrine effects. | From baseline to the primary follow-up (6 and 12 months after the last dose) and thereafter assessed annually to the end of the long-time follow-up (10 years after the first dose). | Paracrine effects will be analysed from plasma isolated from peripheral blood. |
| Assess the potential of non-invasive methods of prenatal diagnosis for OI by genetic analysis of parent DNA. | From baseline to birth for prenatal group. | Non-invasive prenatal diagnosis will be studied during the trial. |
| Impact on the subjects Quality of Life: Infant Toddler Quality of Life Questionnaire™ (ITQOL) | From baseline to the primary follow-up (6 and 12 months after the last dose) and thereafter assessed annually to the end of the long-time follow-up (10 years after the first dose). | Quality of life assessed using the Infant Toddler Quality of Life Questionnaire™ (ITQOL). |
| Incidence of donor cells engrafted into patient tissue samples assessed by histology. | From baseline to the primary follow-up (6 and 12 months after the last dose) and thereafter assessed annually to the end of the long-time follow-up (10 years after the first dose). | Donor cell engraftment. |
Countries
Sweden
Outcome results
None listed